Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Voyager Therapeut (VYGR)

Voyager Therapeut (VYGR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Voyager Provides Update on SOD1 ALS Gene Therapy Program

VYGR : 4.23 (-3.42%)
Voyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference

VYGR : 4.23 (-3.42%)
Axsome Shares Rise 19% in a Month: What's Driving the Rally?

Axsome Therapeutics’ AXSM shares have rallied 19.4% in the past month against the industry’s decrease of 0.2%, driven by investor enthusiasm about the company’s encouraging preliminary sales numbers...

JAZZ : 133.96 (-2.09%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
AXSM : 131.15 (-0.40%)
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?

Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.BEAM’s...

BEAM : 32.40 (+13.25%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
HRMY : 38.98 (-0.24%)
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen (STK-001), its investigational candidate for treating Dravet syndrome, a severe and progressive...

CTMX : 0.7963 (-3.63%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
STOK : 10.68 (+0.47%)
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results

Shares of Mirum Pharmaceuticals MIRM were up 12.1% this week, driven by investor enthusiasm after the company announced encouraging preliminary sales numbers for the fourth quarter and full year 2024,...

CTMX : 0.7963 (-3.63%)
MIRM : 50.04 (-1.30%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)

Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for trofinetide to treat Rett syndrome in...

CTMX : 0.7963 (-3.63%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
ACAD : 20.04 (+1.37%)
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals

Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for trofinetide to treat Rett syndrome in...

CTMX : 0.7963 (-3.63%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
ACAD : 20.04 (+1.37%)
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise

TG Therapeutics TGTX announced preliminary net product revenues for the fourth quarter and full-year 2024 for its marketed drug, Briumvi (ublituximab-xiiy), which exceeded the company’s initial expectations.TGTX...

TGTX : 30.71 (-0.07%)
CTMX : 0.7963 (-3.63%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down

SpringWorks Therapeutics SWTX announced preliminary net product revenues for fourth-quarter and full-year 2024 for its sole marketed drug, Ogsiveo (nirogacestat). The drug is approved for treating adult...

CTMX : 0.7963 (-3.63%)
VYGR : 4.23 (-3.42%)
CSTL : 27.32 (-1.05%)
SWTX : 57.43 (-1.98%)

Barchart Exclusives

Cathie Wood Is Dumping This AI Stock. Should You?
UiPath’s strong Q3 results and AI agent launch are reasons for optimism, but its persistent losses and volatility call for a cautious stance. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar